Is ADC Therapeutics Stock a Good Investment?
ADC Therapeutics Investment Advice | ADCT |
- Examine ADC Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research ADC Therapeutics' leadership team and their track record. Good management can help ADC Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Communications Equipment space and any emerging trends that could impact ADC Therapeutics' business and its evolving consumer preferences.
- Compare ADC Therapeutics' performance and market position to its competitors. Analyze how ADC Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if ADC Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about ADC Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in ADC Therapeutics SA stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if ADC Therapeutics SA is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine ADC Therapeutics Stock
Researching ADC Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 21.0% of the company shares are held by company insiders. The company has Price/Earnings To Growth (PEG) ratio of 0.74. ADC Therapeutics recorded a loss per share of 2.39. The entity had not issued any dividends in recent years.
To determine if ADC Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding ADC Therapeutics' research are outlined below:
| ADC Therapeutics had very high historical volatility over the last 90 days | |
| ADC Therapeutics may become a speculative penny stock | |
| ADC Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 69.56 M. Net Loss for the year was (240.05 M) with loss before overhead, payroll, taxes, and interest of (59.85 M). | |
| ADC Therapeutics SA currently holds about 376.78 M in cash with (118.69 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.9, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 63.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from simplywall.st: Several ADC Therapeutics Insiders Sell Shares Sending Potential Negative Signal |
ADC Therapeutics Quarterly Liabilities And Stockholders Equity |
|
ADC Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in ADC Therapeutics SA. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to ADC Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact ADC Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises ADC Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-07 | 2024-09-30 | -0.38 | -0.42 | -0.04 | 10 | ||
2023-05-09 | 2023-03-31 | -0.67 | -0.74 | -0.07 | 10 | ||
2024-08-06 | 2024-06-30 | -0.46 | -0.38 | 0.08 | 17 | ||
2021-08-03 | 2021-06-30 | -0.86 | -0.96 | -0.1 | 11 | ||
2023-08-08 | 2023-06-30 | -0.46 | -0.58 | -0.12 | 26 | ||
2020-06-03 | 2020-03-31 | -0.56 | -0.77 | -0.21 | 37 | ||
2022-11-08 | 2022-09-30 | -0.35 | -0.65 | -0.3 | 85 | ||
2022-03-03 | 2021-12-31 | -0.86 | -0.45 | 0.41 | 47 |
Know ADC Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as ADC Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading ADC Therapeutics SA backward and forwards among themselves. ADC Therapeutics' institutional investor refers to the entity that pools money to purchase ADC Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-09-30 | 953.2 K | Vantage Consulting Group Inc. | 2024-12-31 | 850.7 K | Blue Owl Capital Holdings Lp | 2024-09-30 | 733.6 K | Bnp Paribas Arbitrage, Sa | 2024-12-31 | 716.7 K | Millennium Management Llc | 2024-09-30 | 712.4 K | Vanguard Group Inc | 2024-12-31 | 644.6 K | Northern Trust Corp | 2024-09-30 | 481 K | Gcm Grosvenor Holdings, Llc | 2024-09-30 | 410.9 K | D. E. Shaw & Co Lp | 2024-09-30 | 284.2 K | Redmile Group, Llc | 2024-09-30 | 15.7 M | Prosight Management, Lp | 2024-09-30 | 9.6 M |
ADC Therapeutics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 154.7 M.Market Cap |
|
ADC Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.61) | (0.64) | |
| Return On Capital Employed | (0.52) | (0.55) | |
| Return On Assets | (0.61) | (0.64) | |
| Return On Equity | 1.46 | 1.53 |
Determining ADC Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if ADC Therapeutics is a good buy. For example, gross profit margin measures ADC Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of ADC Therapeutics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in ADC Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of ADC Therapeutics SA. Check ADC Therapeutics' Beneish M Score to see the likelihood of ADC Therapeutics' management manipulating its earnings.
Evaluate ADC Therapeutics' management efficiency
ADC Therapeutics has return on total asset (ROA) of (0.2117) % which means that it has lost $0.2117 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (7.0553) %, meaning that it created substantial loss on money invested by shareholders. ADC Therapeutics' management efficiency ratios could be used to measure how well ADC Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 1.53 in 2025, whereas Return On Tangible Assets are likely to drop (0.64) in 2025. At this time, ADC Therapeutics' Non Current Liabilities Total is comparatively stable compared to the past year. Non Current Liabilities Other is likely to gain to about 10.7 M in 2025, whereas Total Current Liabilities is likely to drop slightly above 48.6 M in 2025.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (2.09) | (1.98) | |
| Tangible Book Value Per Share | (2.09) | (1.98) | |
| Enterprise Value Over EBITDA | 0.11 | 0.12 | |
| Price Book Value Ratio | (1.05) | (1.00) | |
| Enterprise Value Multiple | 0.11 | 0.12 | |
| Price Fair Value | (1.05) | (1.00) | |
| Enterprise Value | -21.4 M | -20.3 M |
ADC Therapeutics showcases strong leadership that adapts to market changes and drives innovation. Our analysis explores how this adaptability affects the stock's investment appeal.
Beta 1.543 |
Basic technical analysis of ADC Stock
As of the 17th of February 2025, ADC Therapeutics owns the market risk adjusted performance of (3.15), and Variance of 110.64. ADC Therapeutics SA technical analysis gives you the methodology to make use of past data patterns to determine a pattern that approximates the direction of the firm's future prices.ADC Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific ADC Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on ADC Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases ADC Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
ADC Therapeutics' Outstanding Corporate Bonds
ADC Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. ADC Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most ADC bonds can be classified according to their maturity, which is the date when ADC Therapeutics SA has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 4875 Corp BondUS55336VAJ98 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Understand ADC Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing ADC Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (3.15) | |||
| Mean Deviation | 5.96 | |||
| Coefficient Of Variation | (2,494) | |||
| Standard Deviation | 10.52 | |||
| Variance | 110.64 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.43) | |||
| Total Risk Alpha | (0.45) | |||
| Treynor Ratio | (3.16) | |||
| Maximum Drawdown | 99.23 | |||
| Value At Risk | (10.46) | |||
| Potential Upside | 8.78 | |||
| Skewness | 2.83 | |||
| Kurtosis | 21.62 |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (3.15) | |||
| Mean Deviation | 5.96 | |||
| Coefficient Of Variation | (2,494) | |||
| Standard Deviation | 10.52 | |||
| Variance | 110.64 | |||
| Information Ratio | (0.04) | |||
| Jensen Alpha | (0.43) | |||
| Total Risk Alpha | (0.45) | |||
| Treynor Ratio | (3.16) | |||
| Maximum Drawdown | 99.23 | |||
| Value At Risk | (10.46) | |||
| Potential Upside | 8.78 | |||
| Skewness | 2.83 | |||
| Kurtosis | 21.62 |
Consider ADC Therapeutics' intraday indicators
ADC Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of ADC Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
ADC Therapeutics time-series forecasting models is one of many ADC Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary ADC Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
ADC Stock media impact
Far too much social signal, news, headlines, and media speculation about ADC Therapeutics that are available to investors today. That information is available publicly through ADC media outlets and privately through word of mouth or via ADC internal channels. However, regardless of the origin, that massive amount of ADC data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of ADC Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of ADC Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to ADC Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive ADC Therapeutics alpha.
ADC Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards ADC Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
ADC Therapeutics Corporate Directors
| Viviane Monges | Non-Executive Independent Director | Profile | |
| Thomas Pfisterer | Non-Executive Independent Director | Profile | |
| Tyrell Rivers | Non-Executive Independent Director | Profile | |
| Peter Hug | Non-Executive Independent Director | Profile |
Already Invested in ADC Therapeutics SA?
The danger of trading ADC Therapeutics SA is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of ADC Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than ADC Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile ADC Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for ADC Stock Analysis
When running ADC Therapeutics' price analysis, check to measure ADC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADC Therapeutics is operating at the current time. Most of ADC Therapeutics' value examination focuses on studying past and present price action to predict the probability of ADC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADC Therapeutics' price. Additionally, you may evaluate how the addition of ADC Therapeutics to your portfolios can decrease your overall portfolio volatility.